Breaking News

Apotex Names President and CEO

August 27, 2014

Desai brings 30 years of pharma experience

Dr. Jeremy B. Desai has been appointed president and chief executive officer of Apotex replacing Jack Kay, who will serve as vice chairman of the board.
Dr. Desai has 30 years of pharmaceutical experience having held numerous senior positions. Dr. Desai has been with Apotex for the past 11 years, most recently serving as president and chief operating officer, and executive vice president and global head of R&D.
Apotex is among the largest Canadian pharmaceutical companies with more than 5,500 employees in Canada and 10,000 globally. It has exports to 75 countries with planned R&D expenditures of $2.1 billion within the next 10 years.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus